86 results on '"Brioude F"'
Search Results
2. Human Fetal Growth Disorders and Imprinting Anomalies
- Author
-
Gicquel, C., Azzi, S., Rossignol, S., Demars, J., Brioude, F., Netchine, I., Le Bouc, Y., Seckl, Jonathan R, editor, and Christen, Yves, editor
- Published
- 2014
- Full Text
- View/download PDF
3. Régulation de IGF2 et implications périnatales
- Author
-
Brioude, F., primary
- Published
- 2021
- Full Text
- View/download PDF
4. Prevalence and management of gastrointestinal manifestations in Silver–Russell syndrome
- Author
-
Marsaud, Céline, Rossignol, Sylvie, Tounian, Patrick, Netchine, Irène, Dubern, Béatrice, Abadie, V, Alcayde, S, Alembik, Y, Amiel, J, Baujat, G, Baumann-Morel, C, Bieth, E, Bertrand, AM, Bonneau, D, Bouhours Nouet, N, Brachet, C, Brioude, F, Brossier, JP, Boute, O, Cabrol, S, Carel, JC, Chabrol, B, Chivu, O, Christin, P, Collignon, P, Cordier, MP, Cormier Daire, V, Coubes, C, Coupe, B, Coutant, R, Craen, M, Crosnier, H, De Baufort, C, David, A, Delahaye, A, Delobel, B, Delrue, MA, Dieux Coeslier, A, Dommergues, MA, Doray, B, Duban-Bedu, B, Dufresne, S, Edery, P, Esteva, B, Farges, C, Fechtner, I, Francannet, C, Gilbert Dussardier, B, Gilbert, B, Ginglinger, E, Giullano, F, Goldenberg, A, Hamiel, O, Harbison, MD, Heinrichs, C, Heron, D, Holder, M, Houang, M, Genevieve, D, Gerard, M, Gonzales, M, Jantchou, P, Jonveaux, P, Jouk, PS, Kurtz, F, Le Bouc, Y, Le Merrer, M, Linglart, A, Leheup, B, Lebrun, M, Leger, J, Leinhart, A, Loeuille, GA, Manouvrier, S, Martin-Coignard, D, Mas, JC, Mathieu, M, Mercier, S, Mignot, B, Morice-Picard, F, Morin, G, Newfield, R, Odent, S, Oliver-Petit, I, Olivier-Faivre, L, Petriczko, E, Philip, N, Pienkowski, C, Pinson, L, Pinto, G, Polak, M, Quelin, C, Port-lis, M, Reiter, JC, Rio, M, Riviere, MF, Roquelaure, B, Salem, J, Simon, D, Soskin, S, Sznajer, Y, Tauber, M, Thauvin, C, Touraine, R, Teinturier, C, Toutain, A, Van Maldergem, L, Verloes, A, Vincent Delorme, C, Vu-Hong, T-A, and Weill, J
- Published
- 2015
- Full Text
- View/download PDF
5. CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome
- Author
-
Brioude, F, Oliver-Petit, I, Blaise, A, Praz, F, Rossignol, S, Jule, M Le, Thibaud, N, Faussat, A-M, Tauber, M, Bouc, Y Le, and Netchine, I
- Published
- 2013
- Full Text
- View/download PDF
6. Post-Transcriptional Control of Renal Mineralocorticoid Receptor Expression by the mRNA Binding Protein Tis11b and MicroRNAs under Hypertonic Stress.
- Author
-
Viengchareun, S, primary, Keo, V, additional, Meduri, G, additional, Brioude, F, additional, Bouligand, J, additional, Cherradi, N, additional, and Lombes, M, additional
- Published
- 2010
- Full Text
- View/download PDF
7. Panhypopituitarisme congénital par mutation LHX4 : à propos d’un cas
- Author
-
Valentin, C., primary, Legendre, M., additional, Netchine, I., additional, and Brioude, F., additional
- Published
- 2014
- Full Text
- View/download PDF
8. Caractérisation fonctionnelle de 6 variants originaux de KISS1R dans une cohorte de 640 patients atteints d’hypogonadisme hypogonadotrope congénital isolé
- Author
-
Paul, C., primary, Francou, B., additional, Brioude, F., additional, Raffin-Sanson, M.L., additional, Lombès, M., additional, Guiochon-Mantel, A., additional, Young, J., additional, and Bouligand, J., additional
- Published
- 2014
- Full Text
- View/download PDF
9. CDKN1Cmutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome
- Author
-
Brioude, F, primary, Oliver-Petit, I, additional, Blaise, A, additional, Praz, F, additional, Rossignol, S, additional, Jule, M Le, additional, Thibaud, N, additional, Faussat, A-M, additional, Tauber, M, additional, Bouc, Y Le, additional, and Netchine, I, additional
- Published
- 2013
- Full Text
- View/download PDF
10. Beckwith-Wiedemann Syndrome: Growth Pattern and Tumor Risk according to Molecular Mechanism, and Guidelines for Tumor Surveillance
- Author
-
Brioude, F., primary, Lacoste, A., additional, Netchine, I., additional, Vazquez, M.-P., additional, Auber, F., additional, Audry, G., additional, Gauthier-Villars, M., additional, Brugieres, L., additional, Gicquel, C., additional, Le Bouc, Y., additional, and Rossignol, S., additional
- Published
- 2013
- Full Text
- View/download PDF
11. Hypogonadisme hypogonadotrope : notions récentes sur la régulation de l’axe hypothalamo-hypophyso-gonadique
- Author
-
Brioude, F., primary, Bouvattier, C.-E., additional, and Lombès, M., additional
- Published
- 2010
- Full Text
- View/download PDF
12. Beckwith-Wiedemann Syndrome: Growth Pattern and Tumor Risk according to Molecular Mechanism, and Guidelines for Tumor Surveillance.
- Author
-
Brioude, F., Lacoste, a., Netchine, I., Vazquez, M.-P., auber, F., audry, G., Gauthier-Villars, M., Brugieres, L., Gicquel, C., Le Bouc, Y., and Rossignol, S.
- Subjects
- *
BECKWITH-Wiedemann syndrome , *METHYLATION , *TUMORS , *UMBILICAL hernia , *GENES , *PATIENTS - Abstract
Background: Beckwith-Wiedemann syndrome (BWS) is an overgrowth syndrome associated with an increased risk of pediatric tumors. The underlying molecular abnormalities may be genetic (CDKN1C mutations or 11p15 paternal uniparental isodisomy, pUPD) or epigenetic (imprinting center region 1, ICR1, gain of methylation, ICR1 GOM, or ICR2 loss of methylation, ICR2 LOM). Aim: We aimed to describe a cohort of 407 BWS patients with molecular defects of the 11p15 domain followed prospectively after molecular diagnosis. Results: Birth weight and length were significantly higher in patients with ICR1 GOM than in the other groups. ICR2 LOM and CDKN1C mutations were associated with a higher prevalence of exomphalos. Mean adult height (regardless of molecular subtype, n = 35) was 1.8 ± 1.2 SDS, with 18 patients having a final height above +2 SDS. The prevalence of tumors was 8.6% in the whole population; 28.6 and 17.3% of the patients with ICR1 GOM (all Wilms tumors) and 11p15 pUPD, respectively, developed a tumor during infancy. Conversely, the prevalence of tumors in patients with ICR2 LOM and CDKN1C mutations were 3.1 and 8.8%, respectively, with no Wilms tumors. Conclusion: Based on these results for a large cohort, we formulated guidelines for the follow-up of these patients according to the molecular subtype of BWS. © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. [Epigenetics, genomic imprinting and developmental disorders]
- Author
-
Le Bouc Y, Sylvie ROSSIGNOL, Azzi S, Brioude F, Cabrol S, Gicquel C, and Netchine I
14. International consensus group statement on Beckwith-Wiedemann syndrome
- Author
-
Maher, E. R., Brioude, F., Kalish, J. M., Mussa, A., Foster, A., Bliek, J., Ferrero, G. B., Boonen, S., Cole, T., Baker, R., Bertoletti, M., Cocchi, G., Coze, C., Pellegrin, M., Hussain, K., Ibrahim, A., Kilby, M. D., Krajewska-Walasek, M., Kratz, C. P., Ladusans, E. J., Lapunzina, P., Le Bouc, Y., Maas, S., Macdonald, F., Ounap, K., Peruzzi, L., Sylvie ROSSIGNOL, Russo, S., Shipster, C., Skorka, A., Tatton-Brown, K., Tenorio, J., Tortora, C., Gronskov, K., Netchine, I., Hennekam, R. C., Prawitt, D., Tumer, Z., Eggermann, T., Mackay, D. J. G., and Riccio, A.
15. Multi-locus imprinting disturbance (MLID): interim joint statement for clinical and molecular diagnosis.
- Author
-
Mackay DJG, Gazdagh G, Monk D, Brioude F, Giabicani E, Krzyzewska IM, Kalish JM, Maas SM, Kagami M, Beygo J, Kahre T, Tenorio-Castano J, Ambrozaitytė L, Burnytė B, Cerrato F, Davies JH, Ferrero GB, Fjodorova O, Manero-Azua A, Pereda A, Russo S, Tannorella P, Temple KI, Õunap K, Riccio A, de Nanclares GP, Maher ER, Lapunzina P, Netchine I, Eggermann T, Bliek J, and Tümer Z
- Subjects
- Humans, Genetic Testing methods, Genomic Imprinting genetics, DNA Methylation genetics
- Abstract
Background: Imprinting disorders are rare diseases resulting from altered expression of imprinted genes, which exhibit parent-of-origin-specific expression patterns regulated through differential DNA methylation. A subgroup of patients with imprinting disorders have DNA methylation changes at multiple imprinted loci, a condition referred to as multi-locus imprinting disturbance (MLID). MLID is recognised in most but not all imprinting disorders and is also found in individuals with atypical clinical features; the presence of MLID often alters the management or prognosis of the affected person. Some cases of MLID are caused by trans-acting genetic variants, frequently not in the patients but their mothers, which have counselling implications. There is currently no consensus on the definition of MLID, clinical indications prompting testing, molecular procedures and methods for epigenetic and genetic diagnosis, recommendations for laboratory reporting, considerations for counselling, and implications for prognosis and management. The purpose of this study is thus to cover this unmet need., Methods: A comprehensive literature search was conducted resulting in identification of more than 100 articles which formed the basis of discussions by two working groups focusing on clinical diagnosis (n = 12 members) and molecular testing (n = 19 members). Following eight months of preparations and regular online discussions, the experts from 11 countries compiled the preliminary documentation and determined the questions to be addressed during a face-to-face meeting which was held with the attendance of the experts together with four representatives of patient advocacy organisations., Results: In light of available evidence and expert consensus, we formulated 16 propositions and 8 recommendations as interim guidance for the clinical and molecular diagnosis of MLID., Conclusions: MLID is a molecular designation, and for patients with MLID and atypical phenotypes, we propose the alternative term multi-locus imprinting syndrome. Due to the intrinsic variability of MLID, the guidelines underscore the importance of involving experts from various fields to ensure a confident approach to diagnosis, counselling, and care. The authors advocate for global, collaborative efforts in both basic and translational research to tackle numerous crucial questions that currently lack answers, and suggest reconvening within the next 3-5 years to evaluate the research advancements and update this guidance as needed., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. HDR syndrome: Large cohort and systematic review.
- Author
-
Rive Le Gouard N, Lafond-Rive V, Jonard L, Loundon N, Achard S, Heidet L, Mosnier I, Lyonnet S, Brioude F, Serey Gaut M, and Marlin S
- Abstract
HDR syndrome is a rare disease characterized by hypoparathyroidism, deafness, and renal dysplasia. An autosomal dominant disease caused by heterozygous pathogenic GATA3 variants, the penetrance of each associated condition is variable. Literature reviews have provided some answers, but many questions remain, in particular what the relationship is between genotype and phenotype. The current study examines 28 patients with HDR syndrome combined with an exhaustive review of the literature. Some conditions such as hearing loss are almost always present, while others described as rare initially, do not seem to be so rare after all (genital malformations and basal ganglia calcifications). By modeling pathogenic GATA3 variants found in HDR syndrome, we found that missense variations appear to always be located in the same area (close to the two Zinc Finger domain). We describe new pathogenic GATA3 variants, of which some seem to always be associated with certain conditions. Many audiograms were studied to establish a typical audiometric profile associated with a phenotype in HDR. As mentioned in the literature, hearing function should always be assessed as early as possible and follow up of patients with HDR syndrome should include monitoring of parathyroid function and vesicoureteral reflux in order to prevent complications., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
17. Ciliopathy due to POC1A deficiency: clinical and metabolic features, and cellular modeling.
- Author
-
Perge K, Capel E, Villanueva C, Gautheron J, Diallo S, Auclair M, Rondeau S, Morichon R, Brioude F, Jéru I, Rossi M, Nicolino M, and Vigouroux C
- Subjects
- Humans, Cell Cycle Proteins genetics, Cytoskeletal Proteins genetics, Insulin-Like Growth Factor I, Insulin Resistance genetics, Ciliopathies genetics, Abnormalities, Multiple genetics, Insulins
- Abstract
Objective: SOFT syndrome (MIM#614813), denoting Short stature, Onychodysplasia, Facial dysmorphism, and hypoTrichosis, is a rare primordial dwarfism syndrome caused by biallelic variants in POC1A, encoding a centriolar protein. SOFT syndrome, characterized by severe growth failure of prenatal onset and dysmorphic features, was recently associated with insulin resistance. This study aims to further explore its endocrinological features and pathophysiological mechanisms., Design/methods: We present clinical, biochemical, and genetic features of 2 unrelated patients carrying biallelic pathogenic POC1A variants. Cellular models of the disease were generated using patients' fibroblasts and POC1A-deleted human adipose stem cells., Results: Both patients present with clinical features of SOFT syndrome, along with hyperinsulinemia, diabetes or glucose intolerance, hypertriglyceridemia, liver steatosis, and central fat distribution. They also display resistance to the effects of IGF-1. Cellular studies show that the lack of POC1A protein expression impairs ciliogenesis and adipocyte differentiation, induces cellular senescence, and leads to resistance to insulin and IGF-1. An altered subcellular localization of insulin receptors and, to a lesser extent, IGF1 receptors could also contribute to resistance to insulin and IGF1., Conclusions: Severe growth retardation, IGF-1 resistance, and centripetal fat repartition associated with insulin resistance-related metabolic abnormalities should be considered as typical features of SOFT syndrome caused by biallelic POC1A null variants. Adipocyte dysfunction and cellular senescence likely contribute to the metabolic consequences of POC1A deficiency. SOFT syndrome should be included within the group of monogenic ciliopathies with metabolic and adipose tissue involvement, which already encompasses Bardet-Biedl and Alström syndromes., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.)
- Published
- 2024
- Full Text
- View/download PDF
18. First step towards a consensus strategy for multi-locus diagnostic testing of imprinting disorders.
- Author
-
Mackay D, Bliek J, Kagami M, Tenorio-Castano J, Pereda A, Brioude F, Netchine I, Papingi D, de Franco E, Lever M, Sillibourne J, Lombardi P, Gaston V, Tauber M, Diene G, Bieth E, Fernandez L, Nevado J, Tümer Z, Riccio A, Maher ER, Beygo J, Tannorella P, Russo S, de Nanclares GP, Temple IK, Ogata T, Lapunzina P, and Eggermann T
- Subjects
- Humans, Genomic Imprinting, DNA Methylation, Growth Disorders genetics, Diagnostic Techniques and Procedures, Silver-Russell Syndrome diagnosis, Silver-Russell Syndrome genetics, Beckwith-Wiedemann Syndrome diagnosis, Beckwith-Wiedemann Syndrome genetics
- Abstract
Background: Imprinting disorders, which affect growth, development, metabolism and neoplasia risk, are caused by genetic or epigenetic changes to genes that are expressed from only one parental allele. Disease may result from changes in coding sequences, copy number changes, uniparental disomy or imprinting defects. Some imprinting disorders are clinically heterogeneous, some are associated with more than one imprinted locus, and some patients have alterations affecting multiple loci. Most imprinting disorders are diagnosed by stepwise analysis of gene dosage and methylation of single loci, but some laboratories assay a panel of loci associated with different imprinting disorders. We looked into the experience of several laboratories using single-locus and/or multi-locus diagnostic testing to explore how different testing strategies affect diagnostic outcomes and whether multi-locus testing has the potential to increase the diagnostic efficiency or reveal unforeseen diagnoses., Results: We collected data from 11 laboratories in seven countries, involving 16,364 individuals and eight imprinting disorders. Among the 4721 individuals tested for the growth restriction disorder Silver-Russell syndrome, 731 had changes on chromosomes 7 and 11 classically associated with the disorder, but 115 had unexpected diagnoses that involved atypical molecular changes, imprinted loci on chromosomes other than 7 or 11 or multi-locus imprinting disorder. In a similar way, the molecular changes detected in Beckwith-Wiedemann syndrome and other imprinting disorders depended on the testing strategies employed by the different laboratories., Conclusions: Based on our findings, we discuss how multi-locus testing might optimise diagnosis for patients with classical and less familiar clinical imprinting disorders. Additionally, our compiled data reflect the daily life experiences of diagnostic laboratories, with a lower diagnostic yield than in clinically well-characterised cohorts, and illustrate the need for systematising clinical and molecular data., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
19. IGF2 : Development, Genetic and Epigenetic Abnormalities.
- Author
-
Sélénou C, Brioude F, Giabicani E, Sobrier ML, and Netchine I
- Subjects
- Animals, Epigenomics, Genomic Imprinting, Humans, Insulin-Like Growth Factor II genetics, Insulin-Like Growth Factor II metabolism, Mice, Beckwith-Wiedemann Syndrome genetics, Silver-Russell Syndrome genetics
- Abstract
In the 30 years since the first report of parental imprinting in insulin-like growth factor 2 ( Igf2 ) knockout mouse models, we have learnt much about the structure of this protein, its role and regulation. Indeed, many animal and human studies involving innovative techniques have shed light on the complex regulation of IGF2 expression. The physiological roles of IGF-II have also been documented, revealing pleiotropic tissue-specific and developmental-stage-dependent action. Furthermore, in recent years, animal studies have highlighted important interspecies differences in IGF-II function, gene expression and regulation. The identification of human disorders due to impaired IGF2 gene expression has also helped to elucidate the major role of IGF-II in growth and in tumor proliferation. The Silver-Russell and Beckwith-Wiedemann syndromes are the most representative imprinted disorders, as they constitute both phenotypic and molecular mirrors of IGF2 -linked abnormalities. The characterization of patients with either epigenetic or genetic defects altering IGF2 expression has confirmed the central role of IGF-II in human growth regulation, particularly before birth, and its effects on broader body functions, such as metabolism or tumor susceptibility. Given the long-term health impact of these rare disorders, it is important to understand the consequences of IGF2 defects in these patients.
- Published
- 2022
- Full Text
- View/download PDF
20. Low Maternal DLK1 Levels at 26 Weeks Is Associated With Small for Gestational Age at Birth.
- Author
-
Pham A, Mitanchez D, Forhan A, Perin L, Le Bouc Y, Brioude F, Sobrier ML, Heude B, and Netchine I
- Subjects
- Birth Weight, Calcium-Binding Proteins, Female, Fetal Growth Retardation, Gestational Age, Humans, Infant, Newborn, Membrane Proteins, Pregnancy, Pregnancy Trimester, Third, Prospective Studies, Placenta, Ultrasonography, Prenatal
- Abstract
Detecting SGA (small for gestational age) during pregnancy improves the fetal and neonatal prognosis. To date, there is no valid antenatal biomarker of SGA used in clinical practice. Maternal circulating DLK1 (delta-like non-canonical notch ligand 1) levels have been shown to be significantly lower in pregnant women at 36 weeks of gestation (WG) who delivered a SGA newborn than in controls. Data in the literature are contradictory on the association between maternal circulating DLK1 levels and placental vascular dysfunction. The objective was to determine if maternal DLK1 levels in the second trimester of pregnancy are predictive of SGA, and to assess whether the measurement of DLK1 levels in maternal blood could be a means to distinguish SGA with placental vascular dysfunction from that due to other causes. We conducted a nested cased-control study within the EDEN mother-child cohort. 193 SGA (birth weight < 10
th percentile) and 370 mother-child control (birth weight between the 25th and 75th percentile) matched pairs were identified in the EDEN cohort. Maternal circulating DLK1 levels at 26 WG were significantly lower for children born SGA than for controls (27.7 ± 8.7 ng/mL vs 30.4 ± 10.6 ng/mL, p = 0.001). Maternal blood DLK1 levels in the first quartile (DLK1 < 22.85 ng/mL) were associated with an odds ratio for SGA of 1.98 [1.15 - 3.37]. DLK1 was less predictive of SGA than ultrasound, with an area under the curve of 0.578. Maternal circulating DLK1 levels were not significantly different in cases of SGA with signs of placental vascular dysfunction (n = 63, 27.1 ± 9.2 ng/mL) than in those without placental dysfunction (n = 129, 28.0 ± 8.5 ng/mL, p = 0.53). The level of circulating DLK1 is reduced in the second trimester of pregnancy in cases of SGA at birth, independently of signs of placental vascular dysfunction. However, DLK1 alone cannot predict the risk of SGA., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Pham, Mitanchez, Forhan, Perin, Le Bouc, Brioude, Sobrier, Heude and Netchine.)- Published
- 2022
- Full Text
- View/download PDF
21. Screening of patients born small for gestational age with the Silver-Russell syndrome phenotype for DLK1 variants.
- Author
-
Pham A, Sobrier ML, Giabicani E, Le Jules Fernandes M, Mitanchez D, Brioude F, and Netchine I
- Subjects
- Female, Humans, Infant, Newborn, Mutation, Phenotype, Silver-Russell Syndrome diagnosis, Calcium-Binding Proteins genetics, Infant, Small for Gestational Age, Membrane Proteins genetics, Silver-Russell Syndrome genetics
- Abstract
Silver-Russell syndrome (SRS) is a rare imprinting disorder associated with prenatal and postnatal growth retardation. Loss of methylation (LOM) on chromosome 11p15 is observed in 40 to 60% of patients and maternal uniparental disomy (mUPD) for chromosome 7 (upd(7)mat) in ~5 to 10%. Patients with LOM or mUPD 14q32 can present clinically as SRS. Delta like non-canonical Notch ligand 1 (DLK1) is one of the imprinted genes expressed from chromosome 14q32. Dlk1-null mice display fetal growth restriction (FGR) but no genetic defects of DLK1 have been described in human patients born small for gestational age (SGA). We screened a cohort of SGA patients with a SRS phenotype for DLK1 variants using a next-generation sequencing (NGS) approach to search for new molecular defects responsible for SRS. Patients born SGA with a clinical suspicion of SRS and normal methylation by molecular testing at the 11p15 or 14q32 loci and upd(7)mat were screened for DLK1 variants using targeted NGS. Among 132 patients, only two rare variants of DLK1 were identified (NM_003836.6:c.103 G > C (p.(Gly35Arg) and NM_003836.6: c.194 A > G p.(His65Arg)). Both variants were inherited from the mother of the patients, which does not favor a role in pathogenicity, as the mono-allelic expression of DLK1 is from the paternal-inherited allele. We did not identify any pathogenic variants in DLK1 in a large cohort of SGA patients with a SRS phenotype. DLK1 variants are not a common cause of SGA., (© 2021. The Author(s), under exclusive licence to European Society of Human Genetics.)
- Published
- 2021
- Full Text
- View/download PDF
22. Fertility preservation in young men with Klinefelter syndrome: A systematic review.
- Author
-
Ly A, Sermondade N, Brioude F, Berthaut I, Bachelot A, Hamid RH, Khattabi LE, Prades M, Lévy R, and Dupont C
- Subjects
- Adolescent, Fertility Preservation methods, Humans, Infertility, Male etiology, Male, Young Adult, Infertility, Male prevention & control, Klinefelter Syndrome complications
- Abstract
Background: Klinefelter syndrome (KS) is the most common cause of genetic male infertility, as most patients present azoospermia. In the testis, a massive decrease in the number of germinal cells is observed and this can begin early in childhood. Thus, it is possible to collect spermatozoa after sperm collection or thanks to testicular sperm extraction (TESE), but the chances finding spermatozoa are decreasing with the age. Sperm collection or TESE should be performed as early as possible. When KS is diagnosed during childhood or teens, fertility preservation could be beneficial. The minimal age for proposing fertility preservation remains controversial and there is no current recommendation about fertility preservation in young men with KS., Design: In this context, we have conducted a systematic review of the results of fertility preservation in young patients with KS to discuss the optimal age range for offering fertility preservation, including or not a TESE., Results: Six articles were included in the systematic review, with patients between 13 and 24 years-old. Except for one, all young men agreed for sperm collection following masturbation. Azoospermia was diagnosed in all patients presenting homogenous KS. One study reported the presence of spermatozoa in the ejaculate of a young man with mosaic KS. Fifty-eight young man for whom ejaculated sperm collection was unsuccessful have benefited from TESE. Testicular spermatozoa were found and frozen in 27 patients out of the 58 (46.5%). The chances of freezing viable testicular sperm between 14 and 23 years of age do not appear to depend on age., Conclusion: Fertility preservation should be proposed in young men, but the optimal age for proposing the first sperm collection could be adapted according to the medical context and the psychological maturity of the young man., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Unilateral nephrocalcinosis.
- Author
-
Hamroun A, Brioude F, and Lionet A
- Subjects
- Humans, Kidney, Nephrocalcinosis diagnostic imaging
- Published
- 2021
- Full Text
- View/download PDF
24. Increasing knowledge in IGF1R defects: lessons from 35 new patients.
- Author
-
Giabicani E, Willems M, Steunou V, Chantot-Bastaraud S, Thibaud N, Abi Habib W, Azzi S, Lam B, Bérard L, Bony-Trifunovic H, Brachet C, Brischoux-Boucher E, Caldagues E, Coutant R, Cuvelier ML, Gelwane G, Guemas I, Houang M, Isidor B, Jeandel C, Lespinasse J, Naud-Saudreau C, Jesuran-Perelroizen M, Perrin L, Piard J, Sechter C, Souchon PF, Storey C, Thomas D, Le Bouc Y, Rossignol S, Netchine I, and Brioude F
- Subjects
- Abnormalities, Multiple epidemiology, Abnormalities, Multiple physiopathology, Adolescent, Child, Dwarfism genetics, Dwarfism physiopathology, Female, Fetal Growth Retardation epidemiology, Fetal Growth Retardation physiopathology, Growth Disorders epidemiology, Growth Disorders physiopathology, Heterozygote, Homozygote, Humans, Infant, Small for Gestational Age growth & development, Insulin-Like Growth Factor I genetics, Insulin-Like Growth Factor II genetics, Male, Microcephaly genetics, Microcephaly physiopathology, Mutation, Missense genetics, Pedigree, Polymorphism, Single Nucleotide genetics, Receptors, Somatomedin genetics, Abnormalities, Multiple genetics, Fetal Development genetics, Fetal Growth Retardation genetics, Growth Disorders genetics, Receptor, IGF Type 1 genetics
- Abstract
Background: The type 1 insulin-like growth factor receptor (IGF1R) is a keystone of fetal growth regulation by mediating the effects of IGF-I and IGF-II. Recently, a cohort of patients carrying an IGF1R defect was described, from which a clinical score was established for diagnosis. We assessed this score in a large cohort of patients with identified IGF1R defects, as no external validation was available. Furthermore, we aimed to develop a functional test to allow the classification of variants of unknown significance (VUS) in vitro., Methods: DNA was tested for either deletions or single nucleotide variant (SNV) and the phosphorylation of downstream pathways studied after stimulation with IGF-I by western blot analysis of fibroblast of nine patients., Results: We detected 21 IGF1R defects in 35 patients, including 8 deletions and 10 heterozygous, 1 homozygous and 1 compound-heterozygous SNVs. The main clinical characteristics of these patients were being born small for gestational age (90.9%), short stature (88.2%) and microcephaly (74.1%). Feeding difficulties and varying degrees of developmental delay were highly prevalent (54.5%). There were no differences in phenotypes between patients with deletions and SNVs of IGF1R . Functional studies showed that the SNVs tested were associated with decreased AKT phosphorylation., Conclusion: We report eight new pathogenic variants of IGF1R and an original case with a homozygous SNV. We found the recently proposed clinical score to be accurate for the diagnosis of IGF1R defects with a sensitivity of 95.2%. We developed an efficient functional test to assess the pathogenicity of SNVs, which is useful, especially for VUS., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
25. Sleep disordered breathing in Silver-Russell syndrome patients: a new outcome.
- Author
-
Giabicani É, Boulé M, Aubertin G, Galliani E, Brioude F, Dubern B, and Netchine I
- Subjects
- Child, Child, Preschool, Female, Growth Hormone adverse effects, Humans, Male, Polysomnography, Retrospective Studies, Silver-Russell Syndrome complications, Sleep Apnea Syndromes complications, Treatment Outcome, Growth Hormone therapeutic use, Silver-Russell Syndrome diagnosis, Silver-Russell Syndrome drug therapy, Sleep Apnea Syndromes diagnosis
- Abstract
Objective: Imprinting disorders (ID), such as Prader-Willi syndrome (PWS), are associated with sleep-disordered breathing (SDB). No data are available for Silver-Russell syndrome (SRS), another ID that shares clinical features with PWS, although many patients describe excessive daytime sleepiness, disturbed sleep, and snoring. The aim of this study was to characterize sleep in children with SRS and to evaluate the impact of recombinant growth hormone (rGH) therapy., Methods: We performed a retrospective analysis of sleep recordings in 40 patients with molecularly proven SRS (methylation anomaly in 11p15 [n = 32] or maternal uniparental disomy of chromosome 7 [n = 16]). Sleep recordings were either by means of polygraphy or polysomnography (PSG) (n = 16). A total of 34 patients received rGH therapy., Results: We collected 61 sleep recordings. The mean apnea-hypopnea index (AHI) was 3.4 events/h (0-12.4), with a mean central AHI of 0.5 events/h (0-2.4). SDB was identified in 73.8% (n = 45) of the recordings and was severe in 4.9%. SDB was present in 86.4% of patients before rGH therapy and was severe in 13.6%. AHI worsened for 5 of 12 patients with sleep recordings before and after rGH therapy initiation, reaching mild impairment. The mean rGH dose was 32.3 μg/kg/(12.9-51.4), with a mean insulin-like growth factor 1 plasma level of 1.7 SDS (-1.9 to 6.6)., Conclusion: Most patients with SRS present with SDB with an obstructive profile, possibly explained by narrowing of the airways and lymphoid organ hypertrophy. We recommend systematic ear-nose-throat evaluation of SRS patients and PSG if there are clinical anomalies, preferably before initiating rGH therapy, to monitor and adapt the management of patients with SDB., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
26. Contribution of functionally assessed GHRHR mutations to idiopathic isolated growth hormone deficiency in patients without GH1 mutations.
- Author
-
Cohen E, Belkacem S, Fedala S, Collot N, Khallouf E, Dastot F, Polak M, Duquesnoy P, Brioude F, Rose S, Viot G, Soleyan A, Carel JC, Sobrier ML, Chanson P, Gatelais F, Heinrichs C, Kaffel N, Coutant R, Savaş Erdeve Ş, Kurnaz E, Aycan Z, Thalassinos C, Lyonnet S, Şıklar Z, Berberoglu M, Brachet C, Amselem S, and Legendre M
- Subjects
- Alleles, Amino Acid Sequence, Amino Acid Substitution, Cyclic AMP, DNA Mutational Analysis, Dwarfism, Pituitary diagnosis, Female, Genotype, Human Growth Hormone genetics, Humans, Male, Pedigree, Receptors, Neuropeptide chemistry, Receptors, Pituitary Hormone-Regulating Hormone chemistry, Dwarfism, Pituitary genetics, Genetic Association Studies, Genetic Predisposition to Disease, Mutation, Receptors, Neuropeptide genetics, Receptors, Pituitary Hormone-Regulating Hormone genetics
- Abstract
Isolated growth hormone deficiency (IGHD) is a rare condition mainly caused by mutations in GH1. The aim of this study was to assess the contribution of GHRHR mutations to IGHD in an unusually large group of patients. All GHRHR coding exons and flanking intronic regions were sequenced in 312 unrelated patients with nonsyndromic IGHD. Functional consequences of all newly identified missense variants were assessed in vitro (i.e., study of the expression of recombinant GHRHRs and their ability to activate the cyclic adenosine monophosphate (cAMP) signaling pathway). Genotype-phenotype correlation analyses were performed according to the nature of the identified mutation. We identified 20 different disease-causing GHRHR mutations (truncating and missense loss-of-function mutations), among which 15 are novel, in 24 unrelated patients. Of note, about half (13/24) of those patients represent sporadic cases. The clinical phenotype of patients with at least one missense GHRHR mutation was found to be indistinguishable from that of patients with bi-allelic truncating mutations. This study, which unveils disease-causing GHRHR mutations in 8% (24/312) of IGHD cases, identifies GHRHR as the second IGHD gene most frequently involved after GH1. The finding that 8% of IGHD cases without GH1 mutations are explained by GHRHR molecular defects (including missense mutations), together with the high proportion of sporadic cases among those patients, has important implications for genetic counseling., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
27. Overgrowth syndromes - clinical and molecular aspects and tumour risk.
- Author
-
Brioude F, Toutain A, Giabicani E, Cottereau E, Cormier-Daire V, and Netchine I
- Subjects
- Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac genetics, Arrhythmias, Cardiac pathology, Female, Genetic Diseases, X-Linked epidemiology, Genetic Diseases, X-Linked genetics, Genetic Diseases, X-Linked pathology, Gigantism epidemiology, Gigantism genetics, Gigantism pathology, Heart Defects, Congenital epidemiology, Heart Defects, Congenital genetics, Heart Defects, Congenital pathology, Humans, Intellectual Disability epidemiology, Intellectual Disability genetics, Intellectual Disability pathology, Megalencephaly epidemiology, Megalencephaly genetics, Megalencephaly pathology, Neoplasms pathology, Pregnancy, Risk Factors, Sotos Syndrome epidemiology, Sotos Syndrome genetics, Sotos Syndrome pathology, Syndrome, Neoplasms epidemiology, Neoplasms genetics
- Abstract
Overgrowth syndromes are a heterogeneous group of rare disorders characterized by generalized or segmental excessive growth commonly associated with additional features, such as visceromegaly, macrocephaly and a large range of various symptoms. These syndromes are caused by either genetic or epigenetic anomalies affecting factors involved in cell proliferation and/or the regulation of epigenetic markers. Some of these conditions are associated with neurological anomalies, such as cognitive impairment or autism. Overgrowth syndromes are frequently associated with an increased risk of cancer (embryonic tumours during infancy or carcinomas during adulthood), but with a highly variable prevalence. Given this risk, syndrome-specific tumour screening protocols have recently been established for some of these conditions. Certain specific clinical traits make it possible to discriminate between different syndromes and orient molecular explorations to determine which molecular tests to conduct, despite the syndromes having overlapping clinical features. Recent advances in molecular techniques using next-generation sequencing approaches have increased the number of patients with an identified molecular defect (especially patients with segmental overgrowth). This Review discusses the clinical and molecular diagnosis, tumour risk and recommendations for tumour screening for the most prevalent generalized and segmental overgrowth syndromes.
- Published
- 2019
- Full Text
- View/download PDF
28. Roles of Type 1 Insulin-Like Growth Factor (IGF) Receptor and IGF-II in Growth Regulation: Evidence From a Patient Carrying Both an 11p Paternal Duplication and 15q Deletion.
- Author
-
Giabicani E, Chantot-Bastaraud S, Bonnard A, Rachid M, Whalen S, Netchine I, and Brioude F
- Abstract
We report an original association of complex genetic defects in a patient carrying both an 11p paternal duplication, resulting in the double expression of insulin-like growth factor 2 (IGF2) , as reported in Beckwith-Wiedemann syndrome, and a 15q terminal deletion, including the type 1 IGF receptor gene ( IGF1R ), resulting in haploinsufficiency for this gene. The patient was born with measurements appropriate for her gestational age but experienced growth retardation in early childhood, allowing a better comprehension of the IGF system in the pathophysiology of growth. It is possible that IGF-II plays a key role in fetal growth, independently of IGF1R signaling, and that its role is less important in post-natal growth, leaving IGF-I and growth hormone as the main actors.
- Published
- 2019
- Full Text
- View/download PDF
29. CUGC for Simpson-Golabi-Behmel syndrome (SGBS).
- Author
-
Vuillaume ML, Moizard MP, Baumer A, Cottereau E, Brioude F, Rauch A, and Toutain A
- Subjects
- Abnormalities, Multiple physiopathology, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac physiopathology, Female, Genetic Diseases, X-Linked diagnosis, Genetic Diseases, X-Linked physiopathology, Genetic Testing, Gigantism diagnosis, Gigantism physiopathology, Heart Defects, Congenital diagnosis, Heart Defects, Congenital physiopathology, Humans, Intellectual Disability diagnosis, Intellectual Disability physiopathology, Male, Mutation genetics, Phenotype, Abnormalities, Multiple genetics, Arrhythmias, Cardiac genetics, Genetic Diseases, X-Linked genetics, Genetic Predisposition to Disease, Gigantism genetics, Glypicans genetics, Heart Defects, Congenital genetics, Intellectual Disability genetics
- Abstract
Name of the Disease (synonyms): Simpson-Golabi-Behmel syndrome (SGBS). OMIM# OF THE DISEASE: 312870., Name of the Analysed Genes or Dna/chromosome Segments: GPC3. OMIM# OF THE GENE(S): 300037. Review of the analytical and clinical validity as well as of the clinical utility of DNA-based testing for mutations in the GPC3 gene(s) in ⊠ diagnostic, ☐ predictive and ⊠ prenatal settings and for ⊠ risk assessment in relatives.
- Published
- 2019
- Full Text
- View/download PDF
30. Discrepant molecular and clinical diagnoses in Beckwith-Wiedemann and Silver-Russell syndromes.
- Author
-
Mackay DJG, Bliek J, Lombardi MP, Russo S, Calzari L, Guzzetti S, Izzi C, Selicorni A, Melis D, Temple K, Maher E, Brioude F, Netchine I, and Eggermann T
- Subjects
- Beckwith-Wiedemann Syndrome diagnosis, Chromosomes, Human, Pair 11 genetics, DNA Methylation, Genetic Predisposition to Disease genetics, Genetic Testing, Humans, Phenotype, Silver-Russell Syndrome diagnosis, Beckwith-Wiedemann Syndrome genetics, Silver-Russell Syndrome genetics
- Abstract
Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS) are two imprinting disorders associated with opposite molecular alterations in the 11p15.5 imprinting centres. Their clinical diagnosis is confirmed by molecular testing in 50-70% of patients. The authors from different reference centres for BWS and SRS have identified single patients with unexpected and even contradictory molecular findings in respect to the clinical diagnosis. These patients clinically do not fit the characteristic phenotypes of SRS or BWS, but illustrate their clinical heterogeneity. Thus, comprehensive molecular testing is essential for accurate diagnosis and appropriate management, to avoid premature clinical diagnosis and anxiety for the families.
- Published
- 2019
- Full Text
- View/download PDF
31. Transcriptional profiling at the DLK1/MEG3 domain explains clinical overlap between imprinting disorders.
- Author
-
Abi Habib W, Brioude F, Azzi S, Rossignol S, Linglart A, Sobrier ML, Giabicani É, Steunou V, Harbison MD, Le Bouc Y, and Netchine I
- Subjects
- Female, Humans, Male, Calcium-Binding Proteins biosynthesis, Calcium-Binding Proteins genetics, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 11 metabolism, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 14 metabolism, DNA Methylation, Epigenesis, Genetic, Genomic Imprinting, Membrane Proteins biosynthesis, Membrane Proteins genetics, Silver-Russell Syndrome genetics, Silver-Russell Syndrome metabolism
- Abstract
Imprinting disorders (IDs) often affect growth in humans, leading to diseases with overlapping features, regardless of the genomic region affected. IDs related to hypomethylation of the human 14q32.2 region and its DLK1/MEG3 domain are associated with Temple syndrome (TS14). TS14 is a rare type of growth retardation, the clinical signs of which overlap considerably with those of Silver-Russell syndrome (SRS), another ID related to IGF2 down-regulation at 11p15.5 region. We show that 14q32.2 hypomethylation affects expression, not only for genes at this locus but also for other imprinted genes, and especially lowers IGF2 levels at 11p15.5. Furthermore, expression of nonimprinted genes is also affected, some of which are also deregulated in SRS patients. These findings highlight the epigenetic regulation of gene expression at the DLK1/MEG3 domain. Expression profiling of TS14 and SRS patients highlights common signatures, which may account for the clinical overlap observed between TS14 and SRS.
- Published
- 2019
- Full Text
- View/download PDF
32. Mutation update for the GPC3 gene involved in Simpson-Golabi-Behmel syndrome and review of the literature.
- Author
-
Vuillaume ML, Moizard MP, Rossignol S, Cottereau E, Vonwill S, Alessandri JL, Busa T, Colin E, Gérard M, Giuliano F, Lambert L, Lefevre M, Kotecha U, Nampoothiri S, Netchine I, Raynaud M, Brioude F, and Toutain A
- Published
- 2018
- Full Text
- View/download PDF
33. Placental Pathology in Beckwith-Wiedemann Syndrome According to Genotype/Epigenotype Subgroups.
- Author
-
Gaillot-Durand L, Brioude F, Beneteau C, Le Breton F, Massardier J, Michon L, Devouassoux-Shisheboran M, and Allias F
- Subjects
- Adult, Female, Genetic Association Studies, Genotype, Humans, Male, Pregnancy, Retrospective Studies, Beckwith-Wiedemann Syndrome genetics, Beckwith-Wiedemann Syndrome pathology, Placenta pathology
- Abstract
Objectives: To evaluate the frequency of placental pathological lesions in Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder that exhibits etiologic molecular heterogeneity and variable phenotypic expression., Materials and Methods: The study included 60 BWS patients with a proven molecular diagnosis and a placental pathological examination. Placentomegaly, placental mesenchymal dysplasia (PMD), chorangioma/chorangiomatosis, and extravillous trophoblastic (EVT) cytomegaly were evaluated and their frequencies in the different molecular subgroups were compared. Immunohistochemistry and fluorescent in situ hybridization (FISH) were performed on EVT cytomegaly., Results: Placentomegaly was found in 70.9% of cases, PMD in 21.7%, chorangioma/chorangiomatosis in 23.3%, and EVT cytomegaly in 21.7%; there was no significant intergroup difference. EVT cytomegaly showed loss of p57 expression, increased Ki67 proliferating index, and polyploidy on FISH analysis., Conclusions: There was no genotype/epigenotype-phenotype correlation concerning placental lesions in BWS. Diffuse EVT cytomegaly with polyploidy may represent a placental finding suggestive of BWS.
- Published
- 2018
- Full Text
- View/download PDF
34. Corpus Callosum Abnormalities and Short Femurs in Beckwith-Wiedemann Syndrome: A Report of Two Fetal Cases.
- Author
-
Beaufrère A, Bonnière M, Tantau J, Roth P, Schaerer E, Brioude F, Netchine I, Bessières B, Gelot A, Vekemans M, Razavi F, Heron D, and Attié-Bitach T
- Subjects
- Fetus, Humans, Male, Agenesis of Corpus Callosum genetics, Beckwith-Wiedemann Syndrome pathology, Femur abnormalities
- Abstract
Introduction: Beckwith-Wiedemann syndrome (BWS) is the most common overgrowth syndrome. Clinical features are highly variable, including occasional posterior fossa malformations but no femoral shortening., Case Report: We report two fetuses with BWS associated with short femurs and corpus callosum hypoplasia. Case 2 was growth restricted. BWS was confirmed by molecular studies showing a loss of methylation at ICR2 at 11p15 chromosomic region in case 1 and a gain of methylation at ICR1 and a loss of methylation at ICR2 locus in case 2., Conclusion: Although the phenotype and the genotype of BWS is now well-known, the presence of corpus callosum abnormalities and short femurs expand the phenotypic spectrum of the disorder.
- Published
- 2018
- Full Text
- View/download PDF
35. Diagnosis and management of postnatal fetal growth restriction.
- Author
-
Giabicani E, Pham A, Brioude F, Mitanchez D, and Netchine I
- Subjects
- Child, Disease Management, Female, Fetal Growth Retardation therapy, Humans, Male, Pregnancy, Fetal Growth Retardation diagnosis
- Abstract
Fetal growth restriction (FGR) can result from multiple causes, such as genetic, epigenetic, environment, hormonal regulation, or vascular troubles and their potential interaction. The physiopathology of FGR is not yet fully elucidated, but the insulin-like growth factor system is known to play a central role. Specific clinical features can lead to the identification of genetic syndromes in some patients. FGR leads to multiple global health concerns, from the perinatal period, with higher morbidity/mortality, through infancy, with neurodevelopmental, growth, and metabolic issues, to the onset of puberty and later in life, with subfertility and elevated risks of cardiovascular and kidney diseases. Adequate follow-up and therapeutics should be offered to these patients. We first review the main molecular etiologies leading to FGR and their specificities. We then highlight the main issues that FGR can raise later in life before concluding with the proposed management of these children., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
36. Chromosome 14q32.2 Imprinted Region Disruption as an Alternative Molecular Diagnosis of Silver-Russell Syndrome.
- Author
-
Geoffron S, Abi Habib W, Chantot-Bastaraud S, Dubern B, Steunou V, Azzi S, Afenjar A, Busa T, Pinheiro Canton A, Chalouhi C, Dufourg MN, Esteva B, Fradin M, Geneviève D, Heide S, Isidor B, Linglart A, Morice Picard F, Naud-Saudreau C, Oliver Petit I, Philip N, Pienkowski C, Rio M, Rossignol S, Tauber M, Thevenon J, Vu-Hong TA, Harbison MD, Salem J, Brioude F, Netchine I, and Giabicani E
- Subjects
- Adolescent, Adult, Calcium-Binding Proteins, Child, Child, Preschool, Chromosome Deletion, Chromosome Disorders diagnosis, DNA Methylation genetics, Diagnosis, Differential, Female, Genomic Imprinting genetics, Humans, Intercellular Signaling Peptides and Proteins genetics, Male, Membrane Proteins genetics, Phenotype, Puberty, Precocious genetics, RNA, Long Noncoding genetics, Retrospective Studies, Silver-Russell Syndrome diagnosis, Syndrome, Uniparental Disomy, Young Adult, Chromosome Disorders genetics, Chromosomes, Human, Pair 14 genetics, Silver-Russell Syndrome genetics
- Abstract
Context: Silver-Russell syndrome (SRS) (mainly secondary to 11p15 molecular disruption) and Temple syndrome (TS) (secondary to 14q32.2 molecular disruption) are imprinting disorders with phenotypic (prenatal and postnatal growth retardation, early feeding difficulties) and molecular overlap., Objective: To describe the clinical overlap between SRS and TS and extensively study the molecular aspects of TS., Patients: We retrospectively collected data on 28 patients with disruption of the 14q32.2 imprinted region, identified in our center, and performed extensive molecular analysis., Results: Seventeen (60.7%) patients showed loss of methylation of the MEG3/DLK1 intergenic differentially methylated region by epimutation. Eight (28.6%) patients had maternal uniparental disomy of chromosome 14 and three (10.7%) had a paternal deletion in 14q32.2. Most patients (72.7%) had a Netchine-Harbison SRS clinical scoring system ≥4/6, and consistent with a clinical diagnosis of SRS. The mean age at puberty onset was 7.2 years in girls and 9.6 years in boys; 37.5% had premature pubarche. The body mass index of all patients increased before pubarche and/or the onset of puberty. Multilocus analysis identified multiple methylation defects in 58.8% of patients. We identified four potentially damaging genetic variants in genes encoding proteins involved in the establishment or maintenance of DNA methylation., Conclusions: Most patients with 14q32.2 disruption fulfill the criteria for a clinical diagnosis of SRS. These clinical data suggest similar management of patients with TS and SRS, with special attention to their young age at the onset of puberty and early increase of body mass index.
- Published
- 2018
- Full Text
- View/download PDF
37. Revisiting Wilms tumour surveillance in Beckwith-Wiedemann syndrome with IC2 methylation loss, reply.
- Author
-
Brioude F, Hennekam R, Bliek J, Coze C, Eggermann T, Ferrero GB, Kratz C, Bouc YL, Maas SM, Mackay DJG, Maher ER, Mussa A, and Netchine I
- Subjects
- DNA Methylation, Genomic Imprinting, Humans, Methylation, Beckwith-Wiedemann Syndrome genetics, Wilms Tumor genetics
- Published
- 2018
- Full Text
- View/download PDF
38. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement.
- Author
-
Brioude F, Kalish JM, Mussa A, Foster AC, Bliek J, Ferrero GB, Boonen SE, Cole T, Baker R, Bertoletti M, Cocchi G, Coze C, De Pellegrin M, Hussain K, Ibrahim A, Kilby MD, Krajewska-Walasek M, Kratz CP, Ladusans EJ, Lapunzina P, Le Bouc Y, Maas SM, Macdonald F, Õunap K, Peruzzi L, Rossignol S, Russo S, Shipster C, Skórka A, Tatton-Brown K, Tenorio J, Tortora C, Grønskov K, Netchine I, Hennekam RC, Prawitt D, Tümer Z, Eggermann T, Mackay DJG, Riccio A, and Maher ER
- Subjects
- Beckwith-Wiedemann Syndrome complications, Beckwith-Wiedemann Syndrome genetics, DNA Copy Number Variations, DNA Methylation, Humans, Molecular Diagnostic Techniques, Neoplasms, Germ Cell and Embryonal etiology, Polymorphism, Single Nucleotide, Prenatal Diagnosis, Reproductive Techniques, Assisted, Beckwith-Wiedemann Syndrome diagnosis, Beckwith-Wiedemann Syndrome therapy, Consensus
- Abstract
Beckwith-Wiedemann syndrome (BWS), a human genomic imprinting disorder, is characterized by phenotypic variability that might include overgrowth, macroglossia, abdominal wall defects, neonatal hypoglycaemia, lateralized overgrowth and predisposition to embryonal tumours. Delineation of the molecular defects within the imprinted 11p15.5 region can predict familial recurrence risks and the risk (and type) of embryonal tumour. Despite recent advances in knowledge, there is marked heterogeneity in clinical diagnostic criteria and care. As detailed in this Consensus Statement, an international consensus group agreed upon 72 recommendations for the clinical and molecular diagnosis and management of BWS, including comprehensive protocols for the molecular investigation, care and treatment of patients from the prenatal period to adulthood. The consensus recommendations apply to patients with Beckwith-Wiedemann spectrum (BWSp), covering classical BWS without a molecular diagnosis and BWS-related phenotypes with an 11p15.5 molecular anomaly. Although the consensus group recommends a tumour surveillance programme targeted by molecular subgroups, surveillance might differ according to the local health-care system (for example, in the United States), and the results of targeted and universal surveillance should be evaluated prospectively. International collaboration, including a prospective audit of the results of implementing these consensus recommendations, is required to expand the evidence base for the design of optimum care pathways.
- Published
- 2018
- Full Text
- View/download PDF
39. Chromosomal rearrangements in the 11p15 imprinted region: 17 new 11p15.5 duplications with associated phenotypes and putative functional consequences.
- Author
-
Heide S, Chantot-Bastaraud S, Keren B, Harbison MD, Azzi S, Rossignol S, Michot C, Lackmy-Port Lys M, Demeer B, Heinrichs C, Newfield RS, Sarda P, Van Maldergem L, Trifard V, Giabicani E, Siffroi JP, Le Bouc Y, Netchine I, and Brioude F
- Subjects
- Adult, Beckwith-Wiedemann Syndrome pathology, Centromere genetics, Chromosome Aberrations, Chromosomes, Human, Pair 11 genetics, Cyclin-Dependent Kinase Inhibitor p57 genetics, Cytogenetic Analysis, Female, Humans, Insulin-Like Growth Factor II genetics, Male, Mutation, Phenotype, Silver-Russell Syndrome pathology, Telomere genetics, Beckwith-Wiedemann Syndrome genetics, Gene Duplication genetics, Molecular Imprinting, Silver-Russell Syndrome genetics
- Abstract
Background: The 11p15 region contains two clusters of imprinted genes. Opposite genetic and epigenetic anomalies of this region result in two distinct growth disturbance syndromes: Beckwith-Wiedemann (BWS) and Silver-Russell syndromes (SRS). Cytogenetic rearrangements within this region represent less than 3% of SRS and BWS cases. Among these, 11p15 duplications were infrequently reported and interpretation of their pathogenic effects is complex., Objectives: To report cytogenetic and methylation analyses in a cohort of patients with SRS/BWS carrying 11p15 duplications and establish genotype/phenotype correlations., Methods: From a cohort of patients with SRS/BWS with an abnormal methylation profile (using ASMM-RTQ-PCR), we used SNP-arrays to identify and map the 11p15 duplications. We report 19 new patients with SRS (n=9) and BWS (n=10) carrying de novo or familial 11p15 duplications, which completely or partially span either both telomeric and centromeric domains or only one domain., Results: Large duplications involving one complete domain or both domains are associated with either SRS or BWS, depending on the parental origin of the duplication. Genotype-phenotype correlation studies of partial duplications within the telomeric domain demonstrate the prominent role of IGF2 , rather than H19 , in the control of growth. Furthermore, it highlights the role of CDKN1C within the centromeric domain and suggests that the expected overexpression of KCNQ1OT1 from the paternal allele (in partial paternal duplications, excluding CDKN1C ) does not affect the expression of CDKN1C ., Conclusions: The phenotype associated with 11p15 duplications depends on the size, genetic content, parental inheritance and imprinting status. Identification of these rare duplications is crucial for genetic counselling., Competing Interests: Competing interests: None declared., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2018
- Full Text
- View/download PDF
40. Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction.
- Author
-
Abi Habib W, Brioude F, Edouard T, Bennett JT, Lienhardt-Roussie A, Tixier F, Salem J, Yuen T, Azzi S, Le Bouc Y, Harbison MD, and Netchine I
- Subjects
- Cell Line, DNA-Binding Proteins metabolism, Epigenesis, Genetic, Facies, Female, Fetal Growth Retardation diagnosis, Gene Expression Regulation, Developmental, Genetic Association Studies, Genotype, Growth Charts, HMGA2 Protein metabolism, Humans, Insulin-Like Growth Factor II metabolism, Models, Biological, Mutation, Pedigree, Signal Transduction, Silver-Russell Syndrome diagnosis, Silver-Russell Syndrome genetics, Silver-Russell Syndrome metabolism, Whole Genome Sequencing, DNA-Binding Proteins genetics, Fetal Growth Retardation genetics, Fetal Growth Retardation metabolism, Genetic Predisposition to Disease, Genetic Variation, HMGA2 Protein genetics, Insulin-Like Growth Factor II genetics
- Abstract
PurposeFetal growth is a complex process involving maternal, placental and fetal factors. The etiology of fetal growth retardation remains unknown in many cases. The aim of this study is to identify novel human mutations and genes related to Silver-Russell syndrome (SRS), a syndromic form of fetal growth retardation, usually caused by epigenetic downregulation of the potent fetal growth factor IGF2.MethodsWhole-exome sequencing was carried out on members of an SRS familial case. The candidate gene from the familial case and two other genes were screened by targeted high-throughput sequencing in a large cohort of suspected SRS patients. Functional experiments were then used to link these genes into a regulatory pathway.ResultsWe report the first mutations of the PLAG1 gene in humans, as well as new mutations in HMGA2 and IGF2 in six sporadic and/or familial cases of SRS. We demonstrate that HMGA2 regulates IGF2 expression through PLAG1 and in a PLAG1-independent manner.ConclusionGenetic defects of the HMGA2-PLAG1-IGF2 pathway can lead to fetal and postnatal growth restriction, highlighting the role of this oncogenic pathway in the fine regulation of physiological fetal/postnatal growth. This work defines new genetic causes of SRS, important for genetic counseling.
- Published
- 2018
- Full Text
- View/download PDF
41. CHARGE syndrome: a recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and minigene assays.
- Author
-
Legendre M, Rodriguez-Ballesteros M, Rossi M, Abadie V, Amiel J, Revencu N, Blanchet P, Brioude F, Delrue MA, Doubaj Y, Sefiani A, Francannet C, Holder-Espinasse M, Jouk PS, Julia S, Melki J, Mur S, Naudion S, Fabre-Teste J, Busa T, Stamm S, Lyonnet S, Attie-Bitach T, Kitzis A, Gilbert-Dussardier B, and Bilan F
- Subjects
- Child, Computational Biology methods, Humans, Male, Real-Time Polymerase Chain Reaction methods, Sequence Analysis, DNA methods, CHARGE Syndrome genetics, DNA Helicases genetics, DNA-Binding Proteins genetics, Mutation, RNA Splice Sites
- Abstract
CHARGE syndrome is a rare genetic disorder mainly due to de novo and private truncating mutations of CHD7 gene. Here we report an intriguing hot spot of intronic mutations (c.5405-7G > A, c.5405-13G > A, c.5405-17G > A and c.5405-18C > A) located in CHD7 IVS25. Combining computational in silico analysis, experimental branch-point determination and in vitro minigene assays, our study explains this mutation hot spot by a particular genomic context, including the weakness of the IVS25 natural acceptor-site and an unconventional lariat sequence localized outside the common 40 bp upstream the acceptor splice site. For each of the mutations reported here, bioinformatic tools indicated a newly created 3' splice site, of which the existence was confirmed using pSpliceExpress, an easy-to-use and reliable splicing reporter tool. Our study emphasizes the idea that combining these two complementary approaches could increase the efficiency of routine molecular diagnosis.
- Published
- 2018
- Full Text
- View/download PDF
42. Comment on: Juvenile granulosa cell ovarian tumor in a child with Beckwith-Wiedemann syndrome.
- Author
-
Brioude F and Netchine I
- Subjects
- Adolescent, Child, Female, Genomic Imprinting, Granulosa Cells, Humans, Beckwith-Wiedemann Syndrome genetics, Granulosa Cell Tumor
- Published
- 2017
- Full Text
- View/download PDF
43. Formation of upd(7)mat by trisomic rescue: SNP array typing provides new insights in chromosomal nondisjunction.
- Author
-
Chantot-Bastaraud S, Stratmann S, Brioude F, Begemann M, Elbracht M, Graul-Neumann L, Harbison M, Netchine I, and Eggermann T
- Abstract
Background: Maternal uniparental disomy (UPD) of chromosome 7 (upd(7)mat) accounts for approximately 10% of patients with Silver-Russell syndrome (SRS). For upd(7)mat and trisomy 7, a significant number of mechanisms have been proposed to explain the postzygotic formation of these chromosomal compositions, but all have been based on as small number of cases. To obtain the ratio of isodisomy and heterodisomy in UPDs (hUPD, iUPD) and to determine the underlying formation mechanisms, we analysed a large cohort of upd(7)mat patients ( n = 73) by SNP array typing. Based on these data, we discuss the UPDs and their underlying trisomy 7 formation mechanisms., Results: A whole chromosome 7 maternal iUPD was confirmed in 28.8%, a mixture or complete maternal hUPD in 71.2% of patients., Conclusions: We could demonstrate that nondisjunction mechanism affecting chromosome 7 are similar to that of the chromosomes more frequently involved in trisomy (and/or UPD), and that mechanisms other than trisomic rescue have a lower significance than previously suspected. Furthermore, we suggest SNP array typing for future parent- and cell-stage-of origin studies in human aneuploidies as they allow the definite classification of trisomies and UPDs, and provide information on recombinational events and their suggested association with aneuploidy formation.
- Published
- 2017
- Full Text
- View/download PDF
44. Nomenclature and definition in asymmetric regional body overgrowth.
- Author
-
Kalish JM, Biesecker LG, Brioude F, Deardorff MA, Di Cesare-Merlone A, Druley T, Ferrero GB, Lapunzina P, Larizza L, Maas S, Macchiaiolo M, Maher ER, Maitz S, Martinez-Agosto JA, Mussa A, Robinson P, Russo S, Selicorni A, and Hennekam RC
- Abstract
We designate a novel term "isolated lateralized overgrowth" (ILO) for the findings previously described as "isolated hemihypertrophy" and "isolated hemihyperplasia." ILO is defined as lateralized overgrowth in the absence of a recognized pattern of malformations, dysplasia, or morphologic variants. ILO is likely genetically heterogeneous. Further study is required to determine more of the underlying genetic etiologies and potential associations with currently unrecognized patterns of malformation., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
45. Imprinted disorders and growth.
- Author
-
Giabicani É, Brioude F, Le Bouc Y, and Netchine I
- Subjects
- Adult, Epigenesis, Genetic, Female, Fetal Development genetics, Fetal Diseases genetics, Fetal Diseases pathology, Growth Disorders genetics, Humans, Infant, Newborn, Mutation, Pregnancy, Uniparental Disomy, Beckwith-Wiedemann Syndrome genetics, Genomic Imprinting, Silver-Russell Syndrome genetics
- Abstract
Fetal growth is a complex process. Its restriction is associated with morbidity and long-term metabolic consequences. Imprinted genes have a critical role in mammalian fetal growth. Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS) are two imprinting disorders with opposite fetal growth disturbance. SRS is leading to severe fetal and postnatal growth retardation with severe feeding difficulties during early childhood and long-term metabolic consequences and BWS is an overgrowth syndrome with an enhanced risk of tumors during childhood. Epigenetic (abnormal methylation at the imprinting center regions) or genetic (mutations, duplications, uniparental disomy [UPD]) including defects of imprinted genes on chromosome 11 (BWS and SRS), 7 (SRS) and more recently 14 (SRS) have been identified in these two syndromes. In humans, the 11p15 region contains genes important for the regulation of fetal and postnatal growth. This region includes two imprinted domains: the IGF2/H19 domain regulated by imprinting center region 1 (ICR1 or H19/IGF2:IG-DMR) and the CDKN1C/KCNQ1OT1 domain regulated by ICR2 (or KCNQ1OT1: TSS DMR)., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. Study of the Factors Leading to Fetal and Neonatal Dysthyroidism in Children of Patients With Graves Disease.
- Author
-
Banigé M, Estellat C, Biran V, Desfrere L, Champion V, Benachi A, Ville Y, Dommergues M, Jarreau PH, Mokhtari M, Boithias C, Brioude F, Mandelbrot L, Ceccaldi PF, Mitanchez D, Polak M, and Luton D
- Abstract
Context: Neonatal hyperthyroidism was first described in 1912 and in 1964 was shown to be linked to transplacental passage of maternal antibodies. Few multicenter studies have described the perinatal factors leading to fetal and neonatal dysthyroidism., Objective: To show how fetal dysthyroidism (FD) and neonatal dysthyroidism (ND) can be predicted from perinatal variables, in particular, the levels of anti-thyrotropin receptor antibodies (TRAbs) circulating in the mother and child., Design and Patients: This was a retrospective multicenter study of data from the medical records of all patients monitored for pregnancy from 2007 to 2014., Setting: Among 280,000 births, the medical records of 2288 women with thyroid dysfunction were selected and screened, and 417 women with Graves disease and positive for TRAbs during pregnancy were included., Results: Using the maternal TRAb levels, the cutoff value of 2.5 IU/L best predicted for FD, with a sensitivity of 100% and specificity of 64%. Using the newborn TRAb levels, the cutoff value of 6.8 IU/L best predicted for ND, with a sensitivity of 100% and a specificity of 94%. In our study, 65% of women with a history of Graves disease did not receive antithyroid drugs during pregnancy but still had infants at risk of ND., Conclusions: In pregnant women with TRAb levels ≥2.5 IU/L, fetal ultrasound monitoring is essential until delivery. All newborns with TRAb levels ≥6.8 IU/L should be examined by a pediatrician with special attention for thyroid dysfunction and treated, if necessary.
- Published
- 2017
- Full Text
- View/download PDF
47. Diagnosis and management of Silver-Russell syndrome: first international consensus statement.
- Author
-
Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliek J, Canton AP, Chrzanowska KH, Davies JH, Dias RP, Dubern B, Elbracht M, Giabicani E, Grimberg A, Grønskov K, Hokken-Koelega AC, Jorge AA, Kagami M, Linglart A, Maghnie M, Mohnike K, Monk D, Moore GE, Murray PG, Ogata T, Petit IO, Russo S, Said E, Toumba M, Tümer Z, Binder G, Eggermann T, Harbison MD, Temple IK, Mackay DJ, and Netchine I
- Subjects
- Gonadotropin-Releasing Hormone therapeutic use, Human Growth Hormone therapeutic use, Humans, Silver-Russell Syndrome metabolism, Disease Management, Internationality, Silver-Russell Syndrome diagnosis, Silver-Russell Syndrome therapy
- Abstract
This Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver-Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.
- Published
- 2017
- Full Text
- View/download PDF
48. Contribution of LHX4 Mutations to Pituitary Deficits in a Cohort of 417 Unrelated Patients.
- Author
-
Cohen E, Maghnie M, Collot N, Leger J, Dastot F, Polak M, Rose S, Touraine P, Duquesnoy P, Tauber M, Copin B, Bertrand AM, Brioude F, Larizza D, Edouard T, González Briceño L, Netchine I, Oliver-Petit I, Sobrier ML, Amselem S, and Legendre M
- Subjects
- Adolescent, Amino Acid Sequence, Biomarkers metabolism, Blotting, Western, Child, Child, Preschool, Cohort Studies, Female, Follow-Up Studies, Humans, Immunoprecipitation, Infant, Infant, Newborn, Male, Pedigree, Prognosis, Sequence Homology, Amino Acid, Hypopituitarism genetics, LIM-Homeodomain Proteins genetics, Mutation genetics, Transcription Factors genetics
- Abstract
Context: LHX4 encodes a LIM-homeodomain transcription factor that is implicated in early pituitary development. In humans, only 13 heterozygous LHX4 mutations have been associated with congenital hypopituitarism., Objective: The aims of this study were to evaluate the prevalence of LHX4 mutations in patients with hypopituitarism, to define the associated phenotypes, and to characterize the functional impact of the identified variants and the respective role of the 2 LIM domains of LHX4., Design and Patients: We screened 417 unrelated patients with isolated growth hormone deficiency or combined pituitary hormone deficiency associated with ectopic posterior pituitary and/or sella turcica anomalies for LHX4 mutations (Sanger sequencing). In vitro studies were performed to assess the functional consequences of the identified variants., Results: We identified 7 heterozygous variations, including p.(Tyr131*), p.(Arg48Thrfs*104), c.606+1G>T, p.Arg65Val, p.Thr163Pro, p.Arg221Gln, and p.Arg235Gln), that were associated with variable expressivity; 5 of the 7 were also associated with incomplete penetrance. The p.(Tyr131*), p.(Arg48Thrfs*104), p.Ala65Val, p.Thr163Pro, and p.Arg221Gln LHX4 variants are unable to transactivate the POU1F1 and GH promoters. As suggested by transactivation, subcellular localization, and protein-protein interaction studies, p.Arg235Gln is probably a rare polymorphism. Coimmunoprecipitation studies identified LHX3 as a potential protein partner of LHX4. As revealed by functional studies of LIM-defective recombinant LHX4 proteins, the LIM1 and LIM2 domains are not redundant., Conclusion: This study, performed in the largest cohort of patients screened so far for LHX4 mutations, describes 6 disease-causing mutations that are responsible for congenital hypopituitarism. LHX4 mutations were found to be associated with variable expressivity, and most of them with incomplete penetrance; their contribution to pituitary deficits that are associated with an ectopic posterior pituitary and/or a sella turcica defect is ∼1.4% in the 417 probands tested., (Copyright © 2017 by the Endocrine Society)
- Published
- 2017
- Full Text
- View/download PDF
49. 11p15 ICR1 Partial Deletions Associated with IGF2/H19 DMR Hypomethylation and Silver-Russell Syndrome.
- Author
-
Abi Habib W, Brioude F, Azzi S, Salem J, Das Neves C, Personnier C, Chantot-Bastaraud S, Keren B, Le Bouc Y, Harbison MD, and Netchine I
- Subjects
- Child, Preschool, Female, Fibroblasts, Gene Expression, Genetic Association Studies, Genetic Predisposition to Disease, Humans, Male, Pedigree, Chromosomes, Human, Pair 11, DNA Methylation, Genomic Imprinting, Insulin-Like Growth Factor II genetics, RNA, Long Noncoding genetics, Sequence Deletion, Silver-Russell Syndrome genetics
- Abstract
The 11p15 region harbors the IGF2/H19 imprinted domain, implicated in fetal and postnatal growth. Silver-Russell syndrome (SRS) is characterized by fetal and postnatal growth failure, and is caused principally by hypomethylation of the 11p15 imprinting control region 1 (ICR1). However, the mechanisms leading to ICR1 hypomethylation remain unknown. Maternally inherited genetic defects affecting the ICR1 domain have been associated with ICR1 hypermethylation and Beckwith-Wiedemann syndrome (an overgrowth syndrome, the clinical and molecular mirror of SRS), and paternal deletions of IGF2 enhancers have been detected in four SRS patients. However, no paternal deletions of ICR1 have ever been associated with hypomethylation of the IGF2/H19 domain in SRS. We screened for new genetic defects within the ICR1 in a cohort of 234 SRS patients with hypomethylated IGF2/H19 domain. We report deletions close to the boundaries of ICR1 on the paternal allele in one familial and two sporadic cases of SRS with ICR1 hypomethylation. These deletions are associated with hypomethylation of the remaining CBS, and decreased IGF2 expression. These results suggest that these regions are most likely required to maintain methylation after fertilization. We estimate these anomalies to occur in about 1% of SRS cases with ICR1 hypomethylation., (© 2016 WILEY PERIODICALS, INC.)
- Published
- 2017
- Full Text
- View/download PDF
50. EMQN best practice guidelines for the molecular genetic testing and reporting of chromosome 11p15 imprinting disorders: Silver-Russell and Beckwith-Wiedemann syndrome.
- Author
-
Eggermann K, Bliek J, Brioude F, Algar E, Buiting K, Russo S, Tümer Z, Monk D, Moore G, Antoniadi T, Macdonald F, Netchine I, Lombardi P, Soellner L, Begemann M, Prawitt D, Maher ER, Mannens M, Riccio A, Weksberg R, Lapunzina P, Grønskov K, Mackay DJ, and Eggermann T
- Subjects
- Beckwith-Wiedemann Syndrome diagnosis, Europe, Genomic Imprinting, Humans, Silver-Russell Syndrome diagnosis, Societies, Medical, Beckwith-Wiedemann Syndrome genetics, Chromosomes, Human, Pair 11 genetics, Genetic Testing standards, Practice Guidelines as Topic, Silver-Russell Syndrome genetics
- Abstract
Molecular genetic testing for the 11p15-associated imprinting disorders Silver-Russell and Beckwith-Wiedemann syndrome (SRS, BWS) is challenging because of the molecular heterogeneity and complexity of the affected imprinted regions. With the growing knowledge on the molecular basis of these disorders and the demand for molecular testing, it turned out that there is an urgent need for a standardized molecular diagnostic testing and reporting strategy. Based on the results from the first external pilot quality assessment schemes organized by the European Molecular Quality Network (EMQN) in 2014 and in context with activities of the European Network of Imprinting Disorders (EUCID.net) towards a consensus in diagnostics and management of SRS and BWS, best practice guidelines have now been developed. Members of institutions working in the field of SRS and BWS diagnostics were invited to comment, and in the light of their feedback amendments were made. The final document was ratified in the course of an EMQN best practice guideline meeting and is in accordance with the general SRS and BWS consensus guidelines, which are in preparation. These guidelines are based on the knowledge acquired from peer-reviewed and published data, as well as observations of the authors in their practice. However, these guidelines can only provide a snapshot of current knowledge at the time of manuscript submission and readers are advised to keep up with the literature.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.